A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson’s disease. Br J Pharmacol. 2012 Jan 10; Authors: Myöhänen TT, Hannula MJ, Van Elzen… [...]
|
|||||||
|
You are at Home>>Heart & Brain>>Parkinson's Disease>> New pharmacological avenues for the treatment of l-DOPA-induced dyskinesias in Parkinson’s disease: targeting glutamate and adenosine receptors. Expert Opin Investig Drugs. 2012 Jan 11; Authors: Blandini F, Armentero MT … [...] Progression of motor symptoms in Parkinson’s disease. Neurosci Bull. 2012 Feb;28(1):39-48 Authors: Xia R, Mao ZH Abstract Parkinson’s disease (PD) is a chronic progressive neurodegenerative disease that is cl… [...] Apathy in parkinson’s disease: Diagnostic and etiological dilemmas. Mov Disord. 2012 Jan 11; Authors: Starkstein SE Abstract About one-third of patients with Parkinson’s disease (PD) are diagnosed with apathy… [...] Abnormal Activity in the Precuneus during Time Perception in Parkinson’s Disease: An fMRI Study. PLoS One. 2012;7(1):e29635 Authors: Dušek P, Jech R, Sieger T, Vymazal J, Růžička E, Wackermann J, Mueller K Abstra… [...] |
|||||||
|
Copyright © 2012 Science Today Online - All Rights Reserved Google PR: 0 · Alexa Rank: 0 |
|||||||
Recent Comments